Cancer immunotherapy targeting the telomerase reverse transcriptase.
The human telomerase reverse transcriptase (hTERT) is expressed in more than 85% of tumor cells but is usually not found in normal cells, which makes hTERT as an ideal tumor-associate antigen (TAA) to develop potential vaccine specifically destroying cancers without impairing normal tissues in human cancer immunotherapy. Here are reviewed the fundamental advances of studies on immunogenicity of hTERT or its peptides and the early clinical trials using the hTERT vaccine approach in the last decades.
Huo
Long Fei
LF
Open Laboratory of Chemical Biology of the Institute of Molecular Technology, Department of Chemistry, The University of Hong Kong, Pokfulam, China.
Tang
Janice Ws
JW
Huang
Jun Jian
JJ
Huang
Pei Tang
PT
Huang
Cui Fen
CF
Kung
Hsiang Fu
HF
Lin
Marie C
MC
D000951:Antigens, Neoplasm / Q000276:immunology* / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004268:DNA-Binding Proteins / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D010455:Peptides / Q000276:immunology* / Q000627:therapeutic use; D019098:Telomerase / Q000276:immunology* / Q000378:metabolism
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D004268:DNA-Binding Proteins; D010455:Peptides; D019098:Telomerase